Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.

@article{Laurie2011BriefRA,
  title={Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.},
  author={Scott A. Laurie and Ashish Gupta and Quincy S.-C. Chu and Christopher W. Lee and Wojciech Morzycki and Ronald Feld and Alison H Foo and Jean M Seely and John R. Goffin and Francis Laberge and Nevin R Murray and Sanjay Rao and Garth Nicholas and Janessa L. Laskin and T. H. Reiman and Delia Sauciuc and Lesley Seymour},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2011},
  volume={6 11},
  pages={1950-4}
}
INTRODUCTION Malignant pleural mesothelioma (MPM) is an aggressive malignancy that most often presents at an advanced, incurable stage. After the failure of standard first-line cisplatin/antifolate chemotherapy, there is no accepted treatment. The vascular endothelial growth factor pathway may be a relevant therapeutic target in MPM. METHODS This open-labeled phase II trial evaluated single-agent sunitinib, an inhibitor of multiple receptor tyrosine kinases including the vascular endothelial… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Advances in treatment of mesothelioma.

Expert opinion on pharmacotherapy • 2016

Similar Papers

Loading similar papers…